Consumer

Updated with a statement from Glow Wired Magazine splashed some cold water on fertility app Glow's assertion that a new study shows their users have a 40 percent higher likelihood of getting pregnant than those who don't use the app.

GreatCall's app Link A number of companies and organizations focused on helping caregivers have formed a group, called the Caregiver Council, to raise awareness about family caregiver support tools, identify problems that family caregivers face, and create new tools that solve these issues.

Project: EVO, an iOS-based video game intervention developed by Akili Interactive Labs, may be an effective method for improving attention and memory in children with ADHD, according to a poster presented at the American Academy of Child and Adolescent Psychiatry’s 62nd annual meeting today.

Nortek Security and Control (NSC), which bought mPERS and telehealth company Numera Libris this past summer, has announced the first new product from the Numera brand post-acquisition.

Virtuagym has raised $2.

Fitness tracking device developer Garmin has unveiled its first smart scale, called Index Smart Scale, to help its users track weight and related metrics.

IBM Research and Carnegie Mellon University are working on a smartphone app that would help blind and visually impaired people navigate their surroundings, by communicating information about the users surroundings to them via audio cues or vibrations.

Fitbit Surge The Consumer Electronics Association (CEA), which puts on the massive CES event in Las Vegas every January, just published a set of voluntary guidelines for how technology companies should approach privacy and security for personal wellness data collected by wearable devices and other connected wellness devices.

Nearly a year after announcing its direct-to-consumer fitness tracker AmpStrip -- and after raising more than $500,000 on Indiegogo for it -- Fitlinxx has announced that it will not be developing AmpStrip as a fitness tracker, but rather as a medical device.

Almost two years after the FDA first told 23andMe to halt sales on its mail-order direct-to-consumer genetic testing service for disease risks, the company has relaunched a version of its new Personal Genome Service (PGS), which now meets FDA standards.